Adding PSMA PET/CT to the workflow seems to have an impact onthe therapeutic management of biochemical recurrence of prostate cancer, mainly promoting ashift from futile curative treatments to systemic palliative ones. The gene discussed is FOLH1; the disease is Familial prostate cancer.